Opus Genetics develops gene therapies for inherited retinal diseases that can cause severe vision loss. IRD reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 22 | Chardan Capital | Maintained | Buy | |
| Oct 16 | Citizens | Target raised | Buy | |
| Oct 6 | Jones Trading | Maintained | Buy | |
| Oct 2 | Chardan Capital | Target raised | Buy | |
| Sep 10 | Wedbush | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in IRD in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IRD is in one of them and how their past IRD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IRD in an article yet. Here's the latest on the wider market.
About Opus Genetics
Opus Genetics is a biopharmaceutical company based in Durham, North Carolina. It is developing gene therapies meant to restore vision and prevent blindness in people with inherited retinal diseases, including Leber congenital amaurosis, bestrophinopathy and retinitis pigmentosa. The company is also developing a prescription eye solution for other ophthalmic conditions, and its target patients are people facing severe, often early-onset, eye disorders.
- Headquarters
- Durham, NC